Lyell (LYEL) CMO Mattieu Aguirre Receives Award of 47,500 Shares

What Happened

• Jarrad Mattieu Aguirre, Chief Medical Officer of Lyell Immunopharma (LYEL), was granted a derivative equity award of 47,500 shares on 2026-09-10. The reported acquisition price is $0.00, indicating an award/grant rather than an open-market purchase or sale. The award includes restricted stock units and option-style shares that will convert to common stock only as they vest.

Key Details

• Transaction date: 2026-09-10; Transaction type: Award/Acquisition (code A); Price: $0.00 (derivative).
• Total shares reported: 47,500 (derivative securities to be settled in common stock subject to vesting).
• Footnote F1: 14,451 RSUs vest quarterly over a 30-month period beginning July 9, 2026, subject to continued service.
• Footnote F2: Option portion: 12.5% of the option shares vest on February 28, 2027; remaining option shares vest in equal monthly installments over the following 42 months, subject to continued service.
• Shares owned following the transaction: not stated in this filing.
• Filing timeliness: Reported on 2026-09-10 for the same date — no late filing indication.

Context

• This is a time-based equity grant (RSUs and option-style vesting) common for executive compensation; shares are subject to future vesting and are not immediately liquid stock sales. Such awards are routine compensation and do not by themselves indicate a buy/sell view of the market.